ClinicalTrials.gg
RecruitingNCT07335718TECAR THERAPYUpdated Jan 13, 2026

Evaluation of the Effectiveness of Focused Radiofrequency (TECAR) Therapy on Pain, Disability, Function, and Quality of Life in Patients With Lumbar Disc Herniation

An observational study in Lumbar Disc Herniation, sponsored by Ankara City Hospital Bilkent. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Ankara City Hospital Bilkent · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
54
Ages
20 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 121 studies in Intervertebral Disc Displacement with a site in Turkey — 22 open to participants now, 28 under way, none of them phase 3. Intervertebral Disc Displacement · Turkey.

Planned enrollment
28th of 35
54 · median 88
Started
2025
with 17 others
Observational
35 of 121
11 open now
Primary completion
2026-02
later than 14 of 27 live
Registered
97th of 121
by date
Lead sponsor
3 of 121
Ankara City Hospital Bilkent

Among the 121 studies in Intervertebral Disc Displacement with a site in Turkey, this one is the 28th largest by planned enrollment of the 35 observational ones that give a count, is one of 18 that started in 2025, is one of 35 observational ones, reaches primary completion later than 14 of the 27 other live ones, and was the 97th registered.

Intervertebral Disc Displacement

474 studies on the registry are indexed under Intervertebral Disc Displacement; 98 are open to participants now.

Browse Intervertebral Disc Displacement studies →

Open to participants now

22 of the 121 studies in Intervertebral Disc Displacement with a site in Turkey are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 48 Intervertebral Disc Displacement studies recruiting now, 20 (42%) set no upper age limit and 24 (50%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 20 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies in Intervertebral Disc Displacement with a site in Turkey, or all of them as a file.
02

Study summary

Low back pain is a very common health problem in societies, regardless of the underlying cause. Its lifetime prevalence has been reported to be as high as 75-80%. Low back pain negatively affects the quality of life of affected individuals. In addition to diagnostic and treatment costs, it can lead to serious physical disability, resulting in loss of workforce and placing a substantial economic burden on countries. Many different factors play a role in the etiology of low back pain. According to etiology, it can be classified as idiopathic, mechanical, rheumatologic, metabolic, endocrine, infectious, neoplastic, neurologic/psychiatric disorders, and pain of visceral origin. The treatment of low back pain can be classified into medical treatment, physical therapy, percutaneous invasive interventions, and surgical intervention. TECAR therapy is also one of the treatment modalities routinely used in clinical practice. Our aim is to develop more effective physical therapy programs.

Read the detailed description

The study is planned as a prospective, randomized, double-blind trial. According to power analysis, 54 patients will be included to achieve 95% power. Eligible participants will be women or men aged 20-60 years who are diagnosed with lumbar disc herniation, have low back pain lasting longer than 12 weeks, present to the Ankara Bilkent City Hospital Physical Therapy and Rehabilitation Hospital as outpatients, and consent to participate in the study.

According to the study criteria, initial evaluations will be performed by a single Physical Medicine and Rehabilitation physician. Demographic data of eligible patients, including age, sex, height, weight, occupation, and systemic diseases, will be recorded.

Patients will be evaluated before treatment, immediately after treatment, and one month after the end of treatment using the following scales: Visual Analog Scale (VAS) for pain, Numeric Rating Scale (NRS), Quality of Life Scale (SF-36), Roland-Morris Disability Questionnaire, Oswestry Disability Index, Finger-to-Floor Distance Measurement, Beck Depression Inventory, and Lumbar Schober Test.

Patients will be divided into two groups. The first group will receive a home exercise program including lumbar active range of motion exercises and lumbar isometric strengthening exercises, performed five times per week for three weeks according to the level of movement restriction and pain severity, along with TECAR therapy applied by a technician for 20 minutes per session, three days per week, for a total of six sessions.

The second group will receive the same home exercise program-including lumbar active range of motion exercises and lumbar isometric strengthening exercises-performed five times per week for three weeks according to the level of movement restriction and pain severity, along with sham TECAR therapy applied by a technician for 20 minutes per session, three days per week, for a total of six sessions.

03

Conditions studied

  • Lumbar Disc Herniation

Keywords

  • Lumbar Disc Herniation
  • TECAR Therapy
  • Pain
04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients presenting to the outpatient clinic of the Ankara Bilkent City Hospital Physical Therapy and Rehabilitation Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Having low back pain lasting longer than 12 weeks

Having a diagnosis of lumbar disc herniation (bulging, protruded, or extruded)

Being able to comply with the exercise program

Willingness to participate in the study Being between 20 and 60 years of age

Exclusion criteria

Exclusion Criteria:

Being younger than 20 years or older than 60 years

Having a known and/or newly diagnosed

Presence of cardiac implants such as a pacemaker

Having inflammatory low back pain

Having absolute spinal stenosis (anteroposterior diameter of the spinal canal \< 10 mm and anteroposterior diameter of the lateral recess \< 3 mm)

History of surgery due to lumbar disc herniation, lumbar spinal stenosis, vertebral fracture, or similar conditions

Presence of lumbar spondylolisthesis

Patients with sequestered disc herniation

Patients with polyneuropathy

Patients with central pain following stroke

Patients with neurological deficits

Having a diagnosed neurodegenerative disease

Having a systemic musculoskeletal disease

Patients with acute deep vein thrombosis

Pregnancy

Presence of infection at the skin surface where treatment will be applied

Unexplained weight loss

Bladder and/or bowel incontinence

Having received physical therapy modalities or injections for low back pain within the last 1 month

Having cognitive impairment

Refusal to participate in the study

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
54 participants (estimated)
Patient registry
No

Groups and cohorts

  • TECAR Therapy

    Patients with lumbar disc herniation

    Device: TECAR THERAPY

  • sham TECAR Therapy

    Patients with lumbar disc herniation

    Device: TECAR Therapy

Interventions

  • DeviceTECAR THERAPY

    TECAR therapy applied by a technician for 20 minutes per session, three days per week, for a total of six sessions

  • DeviceTECAR Therapy

    TECAR therapy is a new and effective treatment modality.

06

What researchers measure

Primary outcomes

  1. Visual Analog Scale (VAS)

    Zero indicates no pain at all, whereas ten represents the most severe pain imaginable.

    Time frame: Up to 1 month after the end of treatment

Secondary outcomes

  1. Oswestry Disability Index

    The Oswestry Disability Index (ODI) is a standardized questionnaire designed to assess the degree of disability and functional impairment in individuals with lower back pain

    Time frame: Up to 1 month after the end of treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — I am undecided because the study is currently ongoing.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Feb 2026, 13 months after the start.

Of 45 non-industry observational studies under Intervertebral Disc Displacement, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 69. This study's planned 13 months is below that.

Counting every sponsor, half of 49 studies reached it within 35 months; a quarter within 13 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2026
First posted
Jan 13, 2026
StartActual
Jan 1, 2025
Primary completionEst.
Feb 1, 2026
CompletionEst.
Feb 15, 2026
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07335718
Responsible party
Cemre Saymaz (DOCTOR, Ankara City Hospital Bilkent) — Principal investigator
First posted
Jan 13, 2026
Start date
Jan 1, 2025
Primary completion
Feb 1, 2026 (estimated)
Completion
Feb 15, 2026 (estimated)
Last update
Jan 13, 2026

Study contacts

cemre y yılmaz
Contact
saymazcemre@gmail.com
0312 552 60 00

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion